Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,628
archived clinical trials in
Schizophrenia

Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
A 12-week, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
Status: Enrolling
Updated:  5/9/2013
Clinical Research Facility
mi
from
Newark, NJ
Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
A 12-week, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
Status: Enrolling
Updated: 5/9/2013
Clinical Research Facility
mi
from
Newark, NJ
Click here to add this to my saved trials
Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
A 12-week, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
Status: Enrolling
Updated:  5/9/2013
Clinical Research Facility
mi
from
New York, NY
Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
A 12-week, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
Status: Enrolling
Updated: 5/9/2013
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
A 12-week, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
Status: Enrolling
Updated:  5/9/2013
Clinical Research Facility
mi
from
Cleveland, OH
Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
A 12-week, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
Status: Enrolling
Updated: 5/9/2013
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
A 12-week, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
Status: Enrolling
Updated:  5/9/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
A 12-week, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
Status: Enrolling
Updated: 5/9/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
A 12-week, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
Status: Enrolling
Updated:  5/9/2013
Clinical Research Facility
mi
from
Charleston, SC
Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
A 12-week, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
Status: Enrolling
Updated: 5/9/2013
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
A 12-week, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
Status: Enrolling
Updated:  5/9/2013
Clinical Research Facility
mi
from
Dallas, TX
Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
A 12-week, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
Status: Enrolling
Updated: 5/9/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
A 12-week, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
Status: Enrolling
Updated:  5/9/2013
Clinical Research Facility
mi
from
Salt Lake City, UT
Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
A 12-week, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
Status: Enrolling
Updated: 5/9/2013
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Status: Enrolling
Updated:  5/9/2013
Clinical Research Facility
mi
from
Fort Smith, AR
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Status: Enrolling
Updated: 5/9/2013
Clinical Research Facility
mi
from
Fort Smith, AR
Click here to add this to my saved trials
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Status: Enrolling
Updated:  5/9/2013
Clinical Research Facility
mi
from
Santa Clara, CA
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Status: Enrolling
Updated: 5/9/2013
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Status: Enrolling
Updated:  5/9/2013
Clinical Research Facility
mi
from
Washington,
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Status: Enrolling
Updated: 5/9/2013
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Status: Enrolling
Updated:  5/9/2013
Clinical Research Facility
mi
from
Daytona Beach, FL
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Status: Enrolling
Updated: 5/9/2013
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Status: Enrolling
Updated:  5/9/2013
Clinical Research Facility
mi
from
Decatur, GA
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Status: Enrolling
Updated: 5/9/2013
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Status: Enrolling
Updated:  5/9/2013
Clinical Research Facility
mi
from
Park Ridge, IL
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Status: Enrolling
Updated: 5/9/2013
Clinical Research Facility
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Status: Enrolling
Updated:  5/9/2013
Clinical Research Facility
mi
from
Metairie, LA
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Status: Enrolling
Updated: 5/9/2013
Clinical Research Facility
mi
from
Metairie, LA
Click here to add this to my saved trials
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Status: Enrolling
Updated:  5/9/2013
Clinical Research Facility
mi
from
St. Joseph, MO
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Status: Enrolling
Updated: 5/9/2013
Clinical Research Facility
mi
from
St. Joseph, MO
Click here to add this to my saved trials
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Status: Enrolling
Updated:  5/9/2013
Clinical Research Facility
mi
from
Newark, NJ
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Status: Enrolling
Updated: 5/9/2013
Clinical Research Facility
mi
from
Newark, NJ
Click here to add this to my saved trials
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Status: Enrolling
Updated:  5/9/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Status: Enrolling
Updated: 5/9/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Status: Enrolling
Updated:  5/9/2013
Clinical Research Facility
mi
from
Dallas, TX
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Status: Enrolling
Updated: 5/9/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia
Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia -Targeted Affective Remediation Approach (TARA)
Status: Enrolling
Updated:  5/13/2013
San Francisco Veterans Affairs Medical Center
mi
from
San Francisco, CA
Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia
Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia -Targeted Affective Remediation Approach (TARA)
Status: Enrolling
Updated: 5/13/2013
San Francisco Veterans Affairs Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia
Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia -Targeted Affective Remediation Approach (TARA)
Status: Enrolling
Updated:  5/13/2013
Langley Porter Psychiatric Institute, UCSF
mi
from
San Francisco, CA
Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia
Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia -Targeted Affective Remediation Approach (TARA)
Status: Enrolling
Updated: 5/13/2013
Langley Porter Psychiatric Institute, UCSF
mi
from
San Francisco, CA
Click here to add this to my saved trials
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated:  5/22/2013
Clinical Research Facility
mi
from
Little Rock, AR
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated: 5/22/2013
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated:  5/22/2013
Clinical Research Facility
mi
from
San Diego, CA
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated: 5/22/2013
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated:  5/22/2013
Clinical Research Facility
mi
from
Fort Lauderdale, FL
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated: 5/22/2013
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated:  5/22/2013
Clinical Research Facility
mi
from
Atlanta, GA
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated: 5/22/2013
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated:  5/22/2013
Clinical Research Facility
mi
from
Baltimore, MD
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated: 5/22/2013
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated:  5/22/2013
Clinical Research Facility
mi
from
Pascagoula, MS
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated: 5/22/2013
Clinical Research Facility
mi
from
Pascagoula, MS
Click here to add this to my saved trials
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated:  5/22/2013
Clinical Research Facility
mi
from
Teaneck, NJ
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated: 5/22/2013
Clinical Research Facility
mi
from
Teaneck, NJ
Click here to add this to my saved trials
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated:  5/22/2013
Clinical Research Facility
mi
from
Bronx, NY
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated: 5/22/2013
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated:  5/22/2013
Clinical Research Facility
mi
from
Asheville, NC
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated: 5/22/2013
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated:  5/22/2013
Clinical Research Facility
mi
from
Allentown, PA
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated: 5/22/2013
Clinical Research Facility
mi
from
Allentown, PA
Click here to add this to my saved trials
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated:  5/22/2013
Clinical Research Facility
mi
from
Chattanooga, TN
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated: 5/22/2013
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated:  5/22/2013
Clinical Research Facility
mi
from
Houston, TX
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Status: Enrolling
Updated: 5/22/2013
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated:  6/16/2013
Otsuka Investigational Site
mi
from
Chandler, AZ
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated: 6/16/2013
Otsuka Investigational Site
mi
from
Chandler, AZ
Click here to add this to my saved trials
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated:  6/16/2013
Otsuka Investigational Site
mi
from
Anaheim, CA
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated: 6/16/2013
Otsuka Investigational Site
mi
from
Anaheim, CA
Click here to add this to my saved trials
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated:  6/16/2013
Otsuka Investigational Site
mi
from
National City, CA
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated: 6/16/2013
Otsuka Investigational Site
mi
from
National City, CA
Click here to add this to my saved trials
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated:  6/16/2013
Otsuka Investigational Site
mi
from
Oceanside, CA
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated: 6/16/2013
Otsuka Investigational Site
mi
from
Oceanside, CA
Click here to add this to my saved trials
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated:  6/16/2013
Otsuka Investigational Site
mi
from
San Diego, CA
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated: 6/16/2013
Otsuka Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated:  6/16/2013
Otsuka Investigational Site
mi
from
Santa Ana, CA
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated: 6/16/2013
Otsuka Investigational Site
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated:  6/16/2013
Otsuka Investigational Site
mi
from
Highlands Ranch, CO
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated: 6/16/2013
Otsuka Investigational Site
mi
from
Highlands Ranch, CO
Click here to add this to my saved trials
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated:  6/16/2013
Otsuka Investigational Site
mi
from
Norwalk, CT
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated: 6/16/2013
Otsuka Investigational Site
mi
from
Norwalk, CT
Click here to add this to my saved trials
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated:  6/16/2013
Otsuka Investigational Site
mi
from
Altamonte Springs, FL
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated: 6/16/2013
Otsuka Investigational Site
mi
from
Altamonte Springs, FL
Click here to add this to my saved trials
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated:  6/16/2013
Otsuka Investigational Site
mi
from
Bradenton, FL
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated: 6/16/2013
Otsuka Investigational Site
mi
from
Bradenton, FL
Click here to add this to my saved trials
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated:  6/16/2013
Otsuka Investigational Site
mi
from
Hollywood, FL
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated: 6/16/2013
Otsuka Investigational Site
mi
from
Hollywood, FL
Click here to add this to my saved trials
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated:  6/16/2013
Otsuka Investigational Site
mi
from
Maitland, FL
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated: 6/16/2013
Otsuka Investigational Site
mi
from
Maitland, FL
Click here to add this to my saved trials
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated:  6/16/2013
Otsuka Investigational Site
mi
from
Miami, FL
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated: 6/16/2013
Otsuka Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated:  6/16/2013
Otsuka Investigational Site
mi
from
North Miami, FL
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated: 6/16/2013
Otsuka Investigational Site
mi
from
North Miami, FL
Click here to add this to my saved trials
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated:  6/16/2013
Otsuka Investigational Site
mi
from
Orange City, FL
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated: 6/16/2013
Otsuka Investigational Site
mi
from
Orange City, FL
Click here to add this to my saved trials
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated:  6/16/2013
Otsuka Investigational Site
mi
from
Tampa, FL
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated: 6/16/2013
Otsuka Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated:  6/16/2013
Otsuka Investigational Site
mi
from
Atlanta, GA
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated: 6/16/2013
Otsuka Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated:  6/16/2013
Otsuka Investigational Site
mi
from
Hoffman Estates, IL
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Status: Enrolling
Updated: 6/16/2013
Otsuka Investigational Site
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials